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Abstract
Background: Glaucoma is the leading cause of irreversible blindness globally, and treatment involves considerable
cost to stakeholders in healthcare. However, there is infrequent availability of cost information and patterns of
management, especially in developing countries. This study determined the cost of the medical management of
POAG, adherence, and pattern of medication prescription in Ghana.
Methods: A retrospective cross-sectional study involving 891 Primary Open Angle Glaucoma (POAG) cases seen
in the year 2012 at three referral facilities. Demographics, ocular history, resource consumption, medication, test,
surgery and other related cost were extracted from 84 patients who had fully complied with their treatment to
calculate total cost (TC) based on 2012 estimates. Glaucoma drugs prescribed to patients who had adhered to all
their review visits within the period evident from case folders were recorded and analysed for the prescription
pattern.
Results: Out of 891 POAG cases seen in 2012, 351(39.4 %) attended all the required review visits, but only 84 (9.4)
had fully and continually adhered to all their treatment regimes. They comprised 41(48.8 %) males and 43(51.2 %)
females with a mean age of 65 ± 14.8. Majority of the respondents were elderly above 60 year of age (65.5 %). The
total estimated cost for the 84 cases in the year was GH¢ 81,237 ($40,619), comprising GH¢ 72,193 ($36,097) direct
medication cost and GH¢9,045 ($4,523) direct non-medication cost (surgery and test cost), and an average of GH¢
967 ($484) for a mean visit of 5.6 ± 1.1 in the year. A total of 673 glaucoma medications had been prescribed for
351 patients for the year, with timolol being the most prescribed (64.19 %) and monotherapy as the most adopted
form of therapy (61.06 %). Age and income showed concurrent increase with cost (P ≤ 0.05).
Conclusions: Cost of managing glaucoma constitutes a substantial financial burden and influenced the pattern of
medication prescription.
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Background
Glaucoma is a group of optic neuropathies which can
lead to progressive and irreversible visual field damage,
and is currently the leading cause of irreversible blind-
ness in the world [1]. Risk factors that can predispose
one to glaucoma include sustained intraocular pressure
(IOP), age, genetics, race, and prolonged use of steroids.
Other risk factors are concomitant systemic and ocular
conditions such as diabetes and high myopia [1, 2].
Estimates based on published data, in conjunction with
prevalence studies have shown that glaucoma is the sec-
ond leading cause of blindness in the world after cataract,
and it is therefore given due public health importance
globally [3, 4]. In 2010, it was estimated that 60.5 m
people were living with the condition (44.7 m with Pri-
mary Open Angle Glaucoma (POAG)), of whom 11.1 m
are projected to go blind by 2020 (6.7 m will be blind
in both eyes) [5]. In West Africa, the most prevalent
type of glaucoma is POAG with 4 % of the population
said to be suffering from it [6, 7]. As the risk of POAG
increases with age, and with the group of those over 40
years of age constituting more than 25 % of Africa’s
population and growing, more people could be living
with the condition than reported [6]. Recently, Ghana
was ranked as having the second highest rate of glau-
coma cases in the world, and highest in West Africa. It
is estimated that about 8.5 % of the population aged 40
years and older have glaucoma in Ghana, of whom
about 70 % are POAG cases [5, 8, 9].
Surgery is generally considered the standard form of
treatment in POAG [2, 6], but in Ghana there is lack of
uptake of this option due to inadequate access, high cost,
superstition and socio-cultural beliefs which means that
many glaucoma patients are treated medically [8–10].
However when the medical option is preferred, the indef-
inite treatment protocols subject many patients to health
care and financial challenges. Moreover, in Ghana the
National Health Insurance Scheme (NHIS) established
under Act 650 of 2003 by the Government of Ghana is
currently facing financial challenges [10, 11]. The NHIS
enjoins patients to pay an annual renewable premium to
access free health care, including some ophthalmic ser-
vices [10]. However, since the inception of the NHIS in
2003, hospitals out-patient departments have been in-
undated with increasing number of patients forcing the
government to make cuts to some services and medica-
tions, due to delays in paying for the services of health
care providers [11]. Consequently, the list of glaucoma
medications covered by the NHIS which could be pre-
scribed free under the scheme to glaucoma patients if
registered are limited to Acetazolamide (Carbonic
Anhydrase Inhibitor), Betaxolol, Pilocarpine (miotics), and
Timolol (beta blocker) [11]. Unfortunately, the list does
not include more potent medications, such as Latanoprost
(prostaglandin analogue) which have been proven to be
better at lowering IOP [11–13]. Comparatively, the
most effective medications often have higher acquisi-
tion cost forcing many patients to rely on the few se-
lected less expensive drugs. In addition, important
diagnostic tests such as Visual Field Test (VFT) and
Nerve Fiber Layer Assessment (NFLA) are excluded
from the NHIS coverage because of the extra burden it
will place on public funds. But to many patients, the
likelihood of going blind and then not being able to
work or perform activities of daily living is far more ex-
pensive. Therefore, glaucoma is not only a public health
problem but also a developmental problem that must
be confronted. However, there is a lack of adequate in-
formation about cost and patterns of management and
their probable influence on treatment compliance,
which has the potential to affect public health planning
and clinical practice. This study seeks to estimate the
direct costs associated with the medical management of
POAG, examine the pattern of glaucoma drug prescrip-
tion, as well as the adherence to treatment in Ghana.
Methods
The study was a hospital based retrospective cross-
sectional one which involved reviewing all diagnosed glau-
coma cases at three eye referral hospitals in the Central
Region of Ghana, namely the Cape Coast Teaching,
Bishop Ackon Memorial and Our Lady of Grace Hospi-
tals. These hospitals were chosen because they serve as
glaucoma referral centers and cater for a large number of
patients in the Western and Central coastal parts of
Ghana and beyond. Apart from them serving as tertiary
eye referral centers, they also have the full range of eye
care facilities and eye care personnel including, Ophthal-
mic Nurses, Optometrists and Ophthalmologists who
diagnose and manage glaucoma cases seen at these facil-
ities. An initial study period of 2010–2014 was considered
for data collection, but due to the peculiar problem of the
limited number of Ophthalmologist in Ghana [14], there
were frequent periods within the initially chosen period
when Ophthalmologists were not continually present to
see glaucoma at the three facilities. To ensure that POAG
cases in the study had been on therapy for a least a year,
were diagnosed by an Ophthalmologist according to the
International Classification of Diseases (Ninth Revision,
Clinical Modification 365.11; 365.12; 365.04), and were al-
ways reviewed by an Ophthalmologist on their subse-
quent visits, only the year 2012 was selected because it
was the only year during which Ophthalmologists were
concurrently present at the three facilities throughout
the year. Protocols for diagnosed POAG were similar
for the three centers, and involved persistent high IOP,
slight lamp examination of anterior chamber angle
(gonioscopy was not done in all cases), and VFTs. All
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medications prescribed and test conducted were all re-
corded in the patients’ folders.
Patients’ folders were assessed for information on
demographic background, medical and ocular history,
ophthalmologist visits, medications prescribed, surgical
procedures, and clinical tests such as VFT, IOP meas-
urement and refractive assessment which were manu-
ally extracted from the folders and entered into excel
spread sheet by Optometrists who are familiar with this
procedure. Information on prices of few medications
which were unavailable and were obtained outside the
hospital pharmacies and tests conducted at private facil-
ities were acquired through telephone calls to the appro-
priate pharmacies and facilities involved.
In Ghana, as part of glaucoma treatment protocol,
patients are required to report back to the treatment
centers either monthly or every three months for their
cases to reviewed or monitored. Consequently, it was
possible to access compliance rate for review visits and
medications prescribed for the selected period of one
year. Those included in the cost evaluation were above
18 years, had been on continuous treatment for at least
the selected year of 2012, and had fully adhered to all
medications and tests prescribed for them. Due to the
importance of treatment compliance in managing POAG,
attending Ophthalmologist always inquired from patients
about usage of previously prescribed medications as part
of the review protocol, and the patient responses including
all tests are duly recorded in their folders. This inclusion
criterion allowed us to determine full treatment compli-
ance rate, and also guaranteed that the cost evaluation
was robust and free from lost information due to failure
to use medications or undergo tests as prescribed for glau-
coma since such test results are also filed together with
case folders. Those included in the prescription pattern
analysis involved patients who had made all their required
scheduled reviews, and therefore had the folders contain-
ing medications prescribed to cover the selected year.
Patients’ folders which did not meet these requirements
were excluded due to the possible lost information for
periods they missed their visits. Cases of Angle Closure
Glaucoma (ACG) and secondary glaucoma were excluded
because of unrelated expenses [2, 15].
After data on ocular drugs prescribed, each test, and
each resource consumed was collected for each visit
during the study period, an average cost for each visit
was derived as the unit cost of each patient. The aver-
age cost for each visit was then used to estimate the
direct costs associated with each visit as done in other
studies [14, 16–18]. Total costs (TC) per year (PY) con-
stituted the direct medication cost and direct non-
medical cost associated with surgery, and tests such as
VFT, NFLA, IOP and refraction (of which the glaucoma
was the cause) using an average exchange rate (2012)
GH¢2 = $1) [16]. Then an average TC per year was
calculated for the entire sample by dividing the TC by
the total number of cases. Thus, the average TC was ad-
justed for the total number of visits to achieve a unique
TC for each patient. In order to determine the factors that
influenced the cost of glaucoma, the authors regressed
the sample’s TC (which was a weighted average of TC
weighted by the total number of visits to the health fa-
cility for each patient) on some selected socioeconomic
and other factors (P ≤ 0.05). The model used was speci-
fied as
TC ¼ β0 þ β1Ageþ β2Sexþ β3Incomeþ β4Educ
þ β5drugtypei þ εi
Where,
Age was age of respondents in years, Sex was the sex
of respondents as either male or female, income was the
average income of the patient whiles drug type was the
anti-glaucoma medication used by the patient in man-
agement of glaucoma. This variable was broken into the
various types of medication with Timolol as the base. εi
is the stochastic disturbance term. In order to present a
robust result, the authors corrected for heteroscedasti-
city, by making use of robust standard errors. All data
were analysed using the Statistical Package for Social
Sciences (SPSS) 16 and Stata 11.2 which was used for
the linear regression analysis.
The study adhered to the Helsinki Declaration on
Research involving human subjects. Anonymity of pa-
tients whose folders were reviewed was ensured at all
times. This study was reviewed and approved by the
Department of Optometry, University of Cape Coast
and the Eye facilities involved.
Results
A total of 891 diagnosed POAG cases were reviewed for
the selected year of 2012. Out of that total POAG cases,
a significant low proportion 351 (39.4 %) made all their
required review visits, but only 84 had fully adhered to
their treatment regimens. That is, overall only 9.4 %
made all required visits, undertook all tests, and con-
firmed use of all medications prescribed for them as re-
corded in their folders. Only 6 (7 %) had undergone
surgery. Among the 84 who had fully complied with
their treatment, 41 (49 %) were male and 43 (51 %) were
female. The female proportion among those who com-
plied with their treatment was slightly lower than to the
number of female cases 418 (54 %) initially counted but
high compared to the male 473 (46 %). More than half
(59.4 %) were registered with the NHIS. Thirty six (42.9
%) were aged 70 years and above and all registered by
the NHIS. Fifty five (65.5 %) were above the retirement
age (in Ghana) of 60 years, of whom 52 (61.9 %) were
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not involved in any economic activity. More than a quar-
ter of them had no formal education 25 (29.8 %) (Table 1).
Patients on average visited the facilities 6 times. Overall,
the cost of medication prescribed and tests done and re-
corded in the folders of 84 patients who had fully adhered
to their treatment was calculated, the pattern of medica-
tions prescribed to the 351 patients who had made all the
required visits were analysed.
The estimated total cost (PY) for the 84 fully compliant
patients was calculated to be, total medication cost = GH¢
72,193 ($36,087) + total non-medication cost = GH¢9,045
($4,523) = GH¢81,237 ($40.619). An average cost case per
year was determined to be = GH¢ GH¢ 967 ($484).
Assuming if all the POAG 891 cases had fully adhered to
their treatment regime, and followed a similar course of
treatment, the total estimated cost (PY) could have been
GH¢861,597 ($430,799).
The results (Table 2) indicated that sex and educa-
tional status of the patients were not statistically signifi-
cant in accounting for the variations in total estimated
cost. The regression results showed that the model was
a good fit with an R2 of 34 % indicating that 34 % of
the variations in total estimated cost are accounted for
by the regression. The F-statistics also showed that at
less than five percent level of significance, the inde-
pendent variables were jointly significant in accounting
for the variations in total calculated cost. The model
also corrected for the problem of heroscedasticity by
making use of robust standard errors. Age was found to
be important in influencing the variations in total esti-
mated cost such that a unit increase in age will lead to
an increase in total estimated cost by 0.43. Income was
also found to be important in influencing the total esti-
mated cost. A unit increase in income leads to a 0.01
increase in total estimated cost. The size of the coeffi-
cient of income seemed to suggest that it was not so
important in terms of the margin of increase that is
occasioned on total calculated cost. The type of drug
prescribed was also found to be important in influen-
cing total estimated cost. From the regression output,
total estimated cost was influenced more by Xalatan
relative to the other medications. From the table, a unit
increase in the purchase of Xalatan will increase total
cost by 12.03 units. Of all the medications included in
the model, Xalatan was the most expensive, and there-
fore it could be predicted that, if it was prescribed and
used more often by the patients relative to the other medi-
cations, the total calculated cost would be expected to
increase.
Of the 351 cases who made all the required visits for
the year, a total of 673 anti-glaucoma medications had
been prescribed. The medications were grouped ac-
cording to the active ingredient in them. Timolol was
the most prescribed anti-glaucoma medication, repre-
senting 432 (64.19 %) while Dorzolamide was the least
prescribed 1 (0.2 %) (Fig. 1). This translated into beta-
blockers being the most frequently prescribed class of
drugs (Fig. 2). Monotherapy (use of single medication)
Table 1 Distribution of estimated cost among respondents
Demographics Male Female Total cost (Ghcb)
Age (years)
≤30 0 (0a) 2 (4.7) 1950 (2.4)
31–40 1 (2.4) 1 (2.3) 1950 (2.4)
41–50 9 (22.0) 4 (9.3) 12592 (15.5)
51–60 6 (14.6) 6 (14.0) 11617 (14.30
61–70 10 (24.4) 9 (20.9) 18360 (22.6)
70+ 15 (36.6) 21 (48.8) 34769 (42.8)
Educational level
No formal education 4 (9.8) 21 (48.8) 24127 (29.7)
Primary/Basic 12 (29.3) 12 (27.9) 23234 (28.6)
Secondary/Technical/ 9 (22.0) 4 (9.3) 12592 (15.5)
Vocational
Post-secondary/Tertiary 16 (39.0) 6 (14.0) 21284 (26.2)
Income (Ghcb)
0–599 31 (75.6) 42 (97.7) 70676 (87.0)
600–999 6 (14.6) 4 (9.8) 5687 (7.0)
>1000 4 (9.8) 1 (2.3) 4874 (6.0)
Total N = 41 (100) N = 43 (100) 81237 (100)
apercentages are in parenthesis bGhana cedi (2Gh¢ = $1 in 2012 in nominal
terms)
Table 2 Relationship between estimated cost and selected
independent variables
Total cost Coef. Robust
Std. Err
t P > |t| [95 % Conf. interval]
Sex −1.65 3.88 −0.43 0.672 −9.38 6.08
EduStatus
Basic Edu. 5.65 4.02 1.40 0.165 −2.38 13.67
Secondary Edu. 1.85 4.28 0.43 0.667 −6.68 10.38
Higher Edu. −2.92 5.79 −0.5 0.616 −14.47 8.63
Age 0.43 0.10 4.03 0.000a −0.65 0.22
Income 0.01 0.00 2.45 0.017a 0.00 0.020
DrugType
Cusimolol 1.22 7.86 0.16 0.877 −14.44 16.88
Optimol 4.43 6.62 0.67 0.505 −8.76 17.62
Xalatan 12.02 5.64 2.13 0.036a 0.78 23.26
Prostan 7.21 5.68 1.27 0.209 −4.13 18.54
Others 3.74 4.12 0.91 0.367 −4.47 11.96
_cons 32.12 12.73 2.52 0.014 6.74 57.49
a= Indicates significance at 5 %
Number of observations =84. Overall effect [F (11, 72) = 10.85, p = 0.000]
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was also the most used form of therapy in 287(61.06 %)
cases, followed by two drug combination 163 (34.68 %)
(not single vials), and then three drug combinations 20
(4.26 %) (Table 3).
Discussion
This study found that a substantial proportion of
patients (65 %) did not adhere to their scheduled review
visits, and an overall low full adherence rate of less than
10 %. This confirms the well-known finding that a sig-
nificant number of patients fail to fully comply with
their review visits and glaucoma medication precisely
as prescribed. Moreover, it is likely that the non-
adherence rate might even be higher than estimated, if
all cases of POAG had been included. By proportion,
the slightly more female than male found in the sample
may not directly be related to the diagnosed glaucoma,
as sex did not influence the estimated cost. Some stud-
ies have suggested that sex is not linked to POAG,
while others found an association [5, 19–21]. In this
study, the slightly higher number of female than male
in this study may be due to the higher proportion of
female in the Ghana population and not an associated
with POAG cases [22].
Glaucoma medications were found to be the major
cost drivers to treatment as there were only few patients
who had had surgery. The estimated average cost of GH
¢ 967 ($484) per POAG patient per year is high consid-
ering that majority 61.9 % of the patients were less eco-
nomically active and were not involved in any income
generating activities. In 2012, the minimum monthly
wage was 120.96 ($60) and with only 28.4 % of the
Ghana population who were below the international
poverty line of US$1.25 per day (2007–2011), the cost to
the individual could be considered high [23]. There are
Fig. 1 Distribution of anti-glaucoma medication prescribed by trade name
Fig. 2 Distribution of class of anti-glaucoma medications prescribed. CIA: Carbonic Anhydrase Inhibitors PA: Prostaglandin analogs
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recently reported financial challenges facing the Ghana
NHIS therefore the projected TC of GH¢861,597
($430,799) per year (assumed full adherence rate for all
891 patients) can be seen as additional burden for a
country with Gross National Income (GNI) per capita
(2012) of $1550 [22, 23]. On the other hand, the esti-
mated TC could even be higher considering that costs
related to eye care facilities use, equipment use, consul-
tations and public health programs which were not part
the cost evaluation. Additionally, other intangible costs
such as stress, loss of leisure time, failure to participate
in societal activities, modification of social and economic
decisions were not factored in the calculation.
The indefinite management of glaucoma might have
influenced the high proportion of NHIS registration
among the patients. The national registration rate for
the NHIS is reported to be around 70 % according to
Government figures, but a study have suggested the
number could be far lower [22]. The study revealed that,
as many as twice high income earners are registered
unto the scheme compared to the poor because of their
ability to pay an annual renewable premium [22]. In this
study, patients who were found not be registered with
the NHIS could be attributed to their inability to afford
the cost of registration or renewal fee, and this can
possibly be cited to partly account for the gap in adher-
ence rate. Indeed, all individuals who were aged 70 years
and above were on the scheme because they were
granted free registration by law.
The study showed a significant relationship between
age and total estimated cost. Glaucoma is a chronic and
progressive condition that is asymptomatic in its early
stages, resulting in delayed case reporting. In Ghana,
access to eye care is also a challenge to many and
therefore patients might seek care at the advanced
stages when visual defects become manifest [10]. At
more advanced stages of the condition, there is likely to
be an increase in reporting time, more resource con-
sumption, and shift to more expensive medications to
slow progression [12, 13]. The increase in reporting
time could also be attributed to certain factors such as
the elderly having access to some welfare packages such
the free NHIS registration that enabled them increase
the number of hospital visits. The association of cost with
income may also reflect the unequal socio-economic sta-
tus in Ghana, and the link between the purchasing power
(ability to afford) and income.
The pattern of prescription found in the study may
also underline cost implications and prescriber prefer-
ences. The predominance reliance on monotherapy and
particularly the use of Timolol is uncommon in similar
studies [12, 24]. In this study, this can be attributed to a
preference for low-priced medication, its availability on
the NHIS medication list, and prescriber preference
which perhaps is due to the uncomplicated nature of ad-
ministering it alone or in combination with other class
of glaucoma medications [14, 25–28]. Though Acetazol-
amide has some reported systemic side effects mainly
because of its oral route of administration [24], it was
relatively prescribed for short-term use in this study,
probably motivated by the desire to reduce IOP since
the patients could not afford more expensive medica-
tions which has IOP-lowering potency. It is also the least
expensive medication on the NHIS list and may under-
line the higher prescription rate. Other studies have re-
ported it to be one of the least prescribed [29]. On the
contrary, though Latanoprost is known for its potency
for reducing IOP [13, 15], it was less frequently pre-
scribed because of its high acquisition cost.
While the findings from this retrospective study are
consistent with results from similar glaucoma cost esti-
mation studies, a number of methodological limitations
may limit the extrapolation of the data to a national
scale. First, the low rate of adherence among the study
population affected the sample size, and for that matter
the total cost estimation. The costing evaluation method
employed may also have led to underestimation of the TC
because it did not include indirect cost associated POAG
treatment such as facility use, diagnostic, personnel as well
Table 3 Distribution of anti-glaucoma medications prescribed
for 351 patients who attended all reviews for one year






2. Two drug combinationa
Tim + Ace 96 59.6
Bet + Ace 5 3.3
Bim + Lat 51 31.6
Tim + Brimo 4 2.5
Tim + Dorzo 1 0.6
Tim + Bim 1 0.6
Bet + Lat 3 1.8
3. Three drug Combination
Tim + Lat + Brim 4 20
Tim + Bim + Brin 7 35
Tim + Ace + Lat 7 35
Tim + Ace + Pil 2 10
Overall Total 673b 100
aCombinations are not single vials bRepresents individual medication counts
Tim timolol, Ace acetazolamide, Bim bimatoprost, Lat latanoprost, Brimo
brimonidine, Dorzo dorzolamide
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as indirect cost related to transportation for the patients
and escorts. It is also possible some information may have
been lost due to tracking, since the study involved case
audit analysis to extract the relevant information from the
patient folders.
Conclusions
This study has a number of clinical implications for
treating glaucoma patients and financing care. Though
the low full adherence rate found in this study is not all
unexpected in the study population regarding medical
care, the non-compliance to glaucoma medication
maybe detrimental to lowering IOP to slow or halt
vision loss. It is reasonable to imply that the high non-
adherence rate is likely to have led to delayed and
unsuccessful management. Therefore, it is important to
find clinical ways to improve adherence among POAG
patient when the medical treatment option is preferred.
It has long been suggested that daily dose frequency,
forgetfulness, inconvenience and side effects account
for non-adherence among glaucoma patients [30]. This
study found that there were cases of multiple drug
prescription that required frequent dosage which many
patients may find be problematic. For such patients,
single potent drugs that do the work of more than one
drug, as well as drugs that need to be taken as few times a
day as possible would likely enhance compliance. Further,
clinicians need to give clear instructions because inad-
equate communication by practitioners could have influ-
enced the compliance rate and minimised successful
clinical outcomes [31].
The high prevalence of POAG cases in the Ghanaian
population coupled with the chronic nature of the
condition constitutes financial burden to the individual,
and the Government through the NHIS as the largest
provider of public health in Ghana. However, it is
obvious from the study that the prescription pattern of
prescribers were influenced, perhaps partly by the cost
of the drugs. There were poor compliance and adher-
ence to treatment schedule with cost as the main
factor. Notwithstanding the underlying cost, the likeli-
hood of treatment success must be considered the main
factor in choosing the appropriate drugs for a given
patient. The inclusion of unbranded prostaglandin ana-
logues in the NHIS drug list, and including essential
glaucoma diagnostic tests (such as VFT and NFLA) for
those aged 40 years and above in the NHIS may improve
adherence. Moreover, considering the emerging aging
population in Ghana, the failure to carefully estimate cost
implications of treating glaucoma on a National scale has
prospects to undermine eye health and derail the NHIS.
This study can be considered as exploratory, but the find-
ings highlight cost as a major factor in treating glaucoma
patients in Ghana. A more holistic approach that avoids
the underlined limitation will go a long way to safeguard
the visual health of the Ghanaian populace.
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